Gallo P, Piccinno M G, Tavolato B, Innocenti M, Callegaro L, Kirschner G, Bruno R, Chizzolini C, Fiori M G
2nd Department of Neurology, University of Padova, School of Medicine, Italy.
J Neuroimmunol. 1992 Jan;36(1):81-6. doi: 10.1016/0165-5728(92)90033-h.
To assess the effects of monosialoganglioside GM1 on some immunological parameters, 12 healthy men were treated with 100 mg GM1 i.m. daily for 15 days. Before and after treatment, the following were studied: (1) serum levels of antibodies against GM1, asialo-GM1 (aGM1), GM2 and GD1b; (2) serum levels of interleukin (IL)-1 beta, IL-2, soluble IL-2 receptor (sIL-2R), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma); (3) IL-1 beta and TNF-alpha production by peripheral blood monocytes (PBMO). Anti-ganglioside antibody and cytokine serum levels were not affected by exogenous GM1 administration with the exception of a transient increase in anti-GM1 antibody titer observed in one subject. In addition, no inhibition of IL-1 beta and TNF-alpha production by PBMO was observed. These preliminary data do not support a potential immunogenic or immunomodulatory function for in vivo administered GM1.
为评估单唾液酸神经节苷脂GM1对某些免疫学参数的影响，12名健康男性每天接受100毫克GM1肌肉注射，共治疗15天。在治疗前后，研究了以下指标：（1）抗GM1、去唾液酸GM1（aGM1）、GM2和GD1b的血清抗体水平；（2）白细胞介素（IL）-1β、IL-2、可溶性IL-2受体（sIL-2R）、肿瘤坏死因子-α（TNF-α）和干扰素-γ（IFN-γ）的血清水平；（3）外周血单核细胞（PBMO）产生的IL-1β和TNF-α。除了在一名受试者中观察到抗GM1抗体滴度短暂升高外，外源性GM1给药未影响抗神经节苷脂抗体和细胞因子血清水平。此外，未观察到PBMO对IL-1β和TNF-α产生的抑制作用。这些初步数据不支持体内给予GM1具有潜在的免疫原性或免疫调节功能。
